SecBot SecBot

LYEL drug pipeline

Lyell Immunopharma, Inc. · 2 rated drugs
$14.65
+2.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.7%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketPivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.

ronde-cel rondecabtagene autoleucel Updated Nov 6

What to watch

The next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.

Bull case
  • Ronde-cel's 91% ORR and 77% CR in 3L+ LBCL compare favorably to approved CAR T therapies, with a differentiated safety profile (no Grade >=3 CRS) that could support outpatient administration and a competitive advantage.
  • The dual-targeting CD19/CD20 design and CD62L enrichment strategy may address the durability limitations of first-generation CAR T therapies, potentially offering longer-lasting responses.
  • Analyst consensus is strongly bullish: 12 of 14 analysts rate it Buy/Strong Buy, with a mean price target of $37.88 (152.5% upside from the $15 close on Nov 5, 2026).
Bear case
  • Ronde-cel is still unapproved and faces a competitive market dominated by Yescarta (Gilead), Breyanzi (BMS), and Kymriah (Novartis), all established CD19 CAR T therapies with multi-billion-dollar sales and years of real-world data.
  • The PiNACLE trial is single-arm (not randomized) in the 3L+ setting, which may raise the bar for FDA approval if durability data at the pivotal readout (mid-2027) does not clearly exceed existing therapies.
  • The company is pre-revenue and posted a net loss of $45.5M in Q3 2026 alone. Despite the recent financing, additional dilution may be needed to fund commercialization.
● neutral
Impact
PhasePhase 1/2
Time to marketLikely several years away. LYL273 is in Phase 1/2 dose-finding. The End-of-Phase 1 FDA meeting is expected in 2027, after which a potential pivotal Phase 2 trial would need to enroll and read out before any BLA submission, likely no earlier than 2028-2029 if all goes well.

LYL273 Updated Nov 6

What to watch

The next catalysts for LYL273 are additional Phase 1 clinical data and an End-of-Phase 1 meeting with the FDA, both now expected in 2027 (pushed from H2 2026). Positive data and regulatory alignment could open a path to a pivotal Phase 2 trial; a safety or efficacy miss would significantly damage the program's prospects. However, Lyell's primary near-term value driver is ronde-cel (BLA submission H2 2027), so LYL273 updates are secondary for the stock.

Bull case
  • Promising early efficacy: LYL273 showed a 67% overall response rate and 83% disease control rate at the highest dose level in heavily pre-treated, refractory metastatic colorectal cancer patients, a population with very limited options.
  • Improved safety with prophylaxis: The June 2026 update showed a GI prophylaxis regimen reduced Grade >=2 diarrhea/colitis from 55% to 10%, with no Grade 3+ CRS or ICANS, suggesting a manageable safety profile.
  • FDA Fast Track designation: LYL273 received Fast Track from the FDA for mCRC, which can enable more frequent interactions and rolling review.
Bear case
  • Timeline slippage: The End-of-Phase 1 FDA meeting was pushed from H2 2026 to 2027 (announced Sept 10, 2026), signaling slower-than-expected enrollment or dose optimization.
  • Very small efficacy dataset: The 67% ORR cited at acquisition came from just 6 patients at the highest dose level; the broader 50% ORR across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) was based on 12 patients total.
  • Solid tumor CAR T is unproven: No CAR T-cell therapy has been approved for a solid tumor like colorectal cancer. LYL273 faces inherent biological challenges in the tumor microenvironment despite its engineering enhancements.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
May 6, 2026ronde-celFast Track−2.7%−6.7%